Brenda Chahla

Brenda Chahla

Auto-generated profile, based on publicly available information

Brenda Chahla

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in The Oncologist
Verified
Journal Article
Open access
PDF file
BCBrenda Chahla
Brenda Chahla
KPKoustav Pal
Koustav Pal
VBVania Balderrama-Brondani
Vania Balderrama-Brondani
FYFeyza Yaylaci
Feyza Yaylaci
MCMatthew T Campbell
Matthew T Campbell
MHMouhammed Amir Habra
Mouhammed Amir Habra
Image-guided therapies (IGTs) are commonly used in oncology, but their role in adrenocortical carcinoma (ACC) is not well defined. A retrospective review of patients with ACC treated with IGTs. We assessed response to therapy using RECIST v1.1, time to next line of systemic therapy, disease control rate (DCR), local tumor progression-free survival (LTPFS), and complications of IGTs (based on the Common Terminology Criteria for Adverse Events [CTCAE] version 5.0). Our cohort included 26 patients (median age 56 years [range 38-76]; n = 18 female) who had 51 IGT sessions to treat 86 lesions. IGTs modalities included cryoablation (n = 49), microwave ablation (n = 21), combined microwave and bland trans-arterial embolization (n = 8), bland trans-arterial embolization alone (n = 3), radio-embolization (n = 3), and radiofrequency ablation (n = 2). DCR was 81.4% (70 out of 86), of which 66.3% of tumors showed complete response, 18.6% showed progressive disease, 8.1% showed partial response, and 7.0% showed stable disease. LTPFS rates were 73% and 63% at 1 and 2 years, respectively. Fourteen lesions underwent re-ablation for incomplete response on initial treatment. Sixteen patients (61.5%) received new systemic therapy following IGTs, with a median time to systemic therapy of 12.5 months (95% CI: 8.6 months upper limit not reached). There was 1 reported CTCAE grade 3 adverse event (biloma) following IGT. IGT use in properly selected patients with ACC is safe and associated with prolonged disease control and delay in the need for systemic therapy.

1 November 2025 in Journal of Immunotherapy and Precision Oncology
Verified
Journal Article
Open access
BCBrenda Chahla
Brenda Chahla
BSBettzy Stephen
Bettzy Stephen
JSJuhee Song
Juhee Song
VBVania Balderrama-Brondani
Vania Balderrama-Brondani
FYFeyza Yaylaci
Feyza Yaylaci
MHMouhammed Amir Habra
Mouhammed Amir Habra
Introduction: Adrenocortical carcinoma (ACC) is a rare cancer with suboptimal response to chemotherapy. The role of immunotherapy in ACC management is evolving. Methods: An investigator-initiated, open-label, phase 2 clinical trial was performed to ascertain the activity and safety of monotherapy with pembrolizumab (a humanized monoclonal anti-programmed cell death protein 1 antibody) in patients with advanced ACC. This study was part of a basket clinical trial (ClinicalTrials.gov ID: NCT02721732). Study participants were enrolled from August 15, 2016, until December 7, 2020. Pembrolizumab (200 mg) was administered intravenously every 3 weeks. All other lines of therapy, including mitotane, were stopped before pembrolizumab initiation. The primary endpoint was the nonprogression rate (being alive without progression) at 27 weeks, which was objectively assessed by an independent radiology team based on the immune-related response evaluation criteria in solid tumors. Secondary endpoints consisted of adverse events assessed using the Common Terminology Criteria for Adverse Events (version 4.03). Results: We enrolled 23 patients with ACC (13 women [57%]) with a median age of 54 years (range, 31–78 years). Four cases were cortisol producing (17%). The median follow-up calculated by reverse Kaplan-Meier was 66.9 months. Among the 23 patients, three were not evaluable for response; two patients stopped treatment because of toxicity and did not undergo restaging scans, and one patient withdrew consent for follow-up owing to international relocation. Among 20 patients with evaluable response, six (30%) were alive without progression at 27 weeks. We saw no complete responses but did see partial responses in four patients (20%) with a mean duration of response of 17.6 months (95% CI, 9.6–25.6). The median progression-free survival time was 4.0 months (95% CI, 2.0–6.2 months), and the median overall survival time was 15.5 months (95% CI, 6.2–22.8 months). The clinical benefit rate was 30% (complete response, partial response, and stable disease at 27 weeks (after 3 radiographic evaluations). Three treatment-related adverse events were grade 3 or higher. Microsatellite instability statuses were not available. No treatment-related deaths occurred. Conclusions: Single-agent pembrolizumab in the treatment of advanced ACC has potential for durable responses and a manageable safety profile.